Understanding EGFR Mutations and First-Line Treatment

Panelists discuss how understanding EGFR mutations has transformed the treatment landscape for non–small cell lung cancer (NSCLC). They describe how identifying mutations such as exon 19 deletions, L858R substitutions, and rarer variants has enabled more precise, targeted therapy selection.

The discussion compares first-, second-, and third-generation tyrosine kinase inhibitors and outlines how treatment personalization has improved survival and reduced toxicity compared with traditional chemotherapy.

The panel also reviews how early and late-line treatment strategies differ, highlighting the growing preference for targeted, chemotherapy-free regimens that enhance quality of life and align with biomarker-driven oncology practices.